ABSTRACT
OBJECTIVE: To design a homogeneous methodology for the registration and analysis of pharmaceutical interventions performed in Spanish critical adults' care units. METHOD: Observational, prospective and multicenter study. In the first stage, a national registry of pharmaceutical interventions will be agreed upon and subsequently all the pharmaceutical interventions performed on adult patients admitted to Spanish CCUs during eight weeks will be recorded. Variables related to the type of CCU, the drug involved in the intervention, type of intervention (indication, effectiveness, safety), recommendation made by the pharmacist and the degree of acceptance will be evaluated. Risk and incidence will be calculated for each of the medication errors detected. The χ2-squared test or Fisher exact test will be used for categorical variables and Mann-Whitney U or Kruskal-Wallis test for continuous variables. All tests will be performed with a significance level αâ¯=â¯0.05 and confidence intervals with confidence 1- α. DISCUSSION: The results obtained from this project will make it possible to obtain a homogeneous classification of the pharmaceutical interventions performed in CCU, a national record and an evaluation of the weak points with the aim of developing strategies for improvement in the pharmaceutical care of the critically ill patient.
ABSTRACT
OBJECTIVE: To study immune-related adverse events (irAEs) in non-small cell lung cancer (NSCLC) patients treated with nivolumab, as well as to assess whether these reactions could be predictors of further effectiveness of therapy. METHODS: Retrospective, observational and longitudinal study. All NSCLC patients who received nivolumab between February 2015-May 2020 were included. In terms of safety, irAEs and their severity were registered and to evaluate the effectiveness, overall survival (OS) and progression free survival (PFS) were calculated. RESULTS: 75 patients were included. 32 patients (43%) were reported irAES. Mainly the irAEs affected the skin (36%). Followed by pneumonitis (20%), gastrointestinal reactions (12%), endocrine (12%) and hepatitis (12%). Regarding severity, 92% were moderate. The median PFS was 9.49 months on the group with irAEs versus 1.99 months on the group without irAEs group (p < 0.0001). The median OS was 17.44 months versus 7.67 months respectively (p = 0.0001). According to the incidence of irAEs developed ( = > 2 vs. 1 vs. 0), the median PFS was 20.53 versus 5.35 versus 1.99 months respectively (p < 0.0001). The median OS was 23.41 versus 15.80 versus 7.67 months, respectively (p = 0.0002). CONCLUSION: In a significant number of patients irAEs occur, generally of grade 1-2 severity, affecting mainly the skin, lungs and gastrointestinal system. We confirm that the development of irAEs in patients with NSCLC treated with nivolumab is a strong predictor of treatment effectiveness in both PFS and OS, with statistically significant results. On those patients who experience two or more immunorelated adverse events the greatest benefit has been observed.
Subject(s)
Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Humans , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/epidemiology , Nivolumab/adverse effects , Lung Neoplasms/drug therapy , Lung Neoplasms/epidemiology , Retrospective Studies , Longitudinal StudiesABSTRACT
OBJECTIVES: Dalbavancin is approved for the treatment of complicated skin and soft tissue infections. However, there is growing evidence that other gram-positive infections could be treated with this antibiotic. A study was undertaken in a tertiary hospital in Spain to evaluate the effectiveness and safety of dalbavancin in off-label indications and the potential healthcare cost savings. METHODS: A retrospective observational study including all patients treated with dalbavancin in our hospital from October 2016 to August 2019 was carried out. Demographic, clinical and safety variables were collected. Effectiveness was assessed using the clinical and microbiological resolution of the infection and the absence of hospital admissions due to the same infection in the following 3 months. RESULTS: A total of 102 patients were included (69.9% men, n=71; median age 72.5 years (range 56.0-84.0)). Treatment was off label in 71 cases (69.6%). The most frequent off-label indications were catheter-related bacteraemia (15.7%, n=16) and endocarditis (13.6%, n=14). All patients had previously received antibiotics. The main reason for switching to dalbavancin was patient discharge (79.4%, n=81). Dalbavancin was administered during hospitalisation in 66.7% of the patients and in the outpatient setting in 13.7%. The median reduction in length of hospital stay was 14 days per patient. A saving of about 4550 Euros per patient was estimated. 89 patients (93.7%) had clinical and microbiological resolution of the infection at the end of the study. One patient did not finish the dalbavancin infusion due to an allergic reaction. CONCLUSIONS: Our results suggest that dalbavancin is a safe and effective alternative to the off-label treatment of gram-positive infections. Its dosage facilitates early discharge and outpatient management of these patients.
Subject(s)
Soft Tissue Infections , Teicoplanin , Aged , Aged, 80 and over , Anti-Bacterial Agents/adverse effects , Female , Health Care Costs , Humans , Male , Middle Aged , Soft Tissue Infections/chemically induced , Soft Tissue Infections/drug therapy , Soft Tissue Infections/microbiology , Teicoplanin/adverse effects , Teicoplanin/analogs & derivativesABSTRACT
OBJECTIVE: Intravenous (IV) tocilizumab has been used to stop the inflammatory phase of SARS-CoV-2 infection. To preserve the largest number of IV units for this use, the Spanish Agency for Medicines and Health Products (AEMPS) carried out a controlled supply of it and recommended the change to a subcutaneous presentation (SC) of tocilizumab or sarilumab in all those patients in IV tocilizumab treatment for rheumatologic indications. The objective of this study was to evaluate the change from IV tocilizumab to SC presentation due to its controlled supply during the COVID-19 pandemic. METHODS: Retrospective observational study of adult patients (>18 years old) under treatment with IV tocilizumab follow-up by the Rheumatology Service of the Hospital 12 de Octubre. The follow-up period was 3 months (March 2020-June 2020) and 39 patients were included in the study. Variables related to the patients and their treatment were collected. A descriptive analysis of the data was carried out. RESULTS: In 69.23% (n=27) of the patients, treatment was changed to SC tocilizumab (n=23) or sarilumab (n=4). 44% of patients (n=12) switched back to their original IV tocilizumab treatment. The reasons for stopping treatment with SC tocilizumab were: drug intolerance (n=4), disease worsening (n=4), and patient preference (n=1). Regarding sarilumab, the reasons were drug intolerance (n=2) and patient preference (n=1). CONCLUSIONS: Almost half of the patients had to return to the original treatment. The main reason was intolerance to the new treatment, followed by ineffectiveness and patient preferences.
OBJETIVO: El tocilizumab intravenoso (IV) ha sido empleado para frenar la fase inflamatoria de la infección por SARS-CoV-2. Para reservar el mayor número de unidades IV para este uso, la Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) realizó una distribución controlada del mismo y recomendó el cambio a una presentación subcutánea (SC), fuera tocilizumab o sarilumab, en todos aquellos pacientes en tratamiento con tocilizumab IV para indicaciones reumatológicas. El objetivo de este trabajo fue evaluar el cambio de tocilizumab IV a una presentación SC debido a su suministro controlado durante la pandemia de COVID-19. METODOS: Se realizó un estudio observacional retrospectivo de pacientes adultos (mayores de 18 años) en tratamiento con tocilizumab IV en seguimiento por el Servicio de Reumatología del Hospital 12 de octubre (Madrid). El periodo de seguimiento fue de tres meses (marzo 2020-junio 2020) y se incluyeron 39 pacientes en el estudio. Se recogieron variables relacionadas con el paciente y su tratamiento. Se realizó un análisis descriptivo de los datos. RESULTADOS: En el 69,23% (n=27) de los pacientes se cambió el tratamiento a tocilizumab SC (n=23) o sarilumab (n=4). El 44% (n=12) de los pacientes volvieron a cambiar a su tratamiento original con tocilizumab IV. Los motivos de interrupción de tratamiento con tocilizumab SC fueron: intolerancia al fármaco (n=4), empeoramiento de la enfermedad (n=4) y preferencia del paciente (n=1). Respecto al sarilumab, los motivos fueron intolerancia al fármaco (n=2) y preferencia del paciente (n=1). CONCLUSIONES: Casi la mitad de los pacientes tuvieron que volver al tratamiento original. El principal motivo fue intolerancia al nuevo tratamiento, seguido de ineficacia y preferencias del paciente.
